Valsartan (Angiotan or Diovan) is an angiotensin II receptor antagonist (more commonly called an ARB, or angiotensin receptor blocker), with particularly high affinity for the type I (AT1) angiotensin receptor. In December 1996, Valsartan was approved by FDA. In the US, UK and Australia, valsartan is marketed by Novartis under the trade name Diovan. In 1998, Valsartan was registered by Novartis in China with ""Daiwen"" as its brand name. After Valsartan, Novartis developed Valsartan compound preparation. In October 1997, valsartan/hydrochlorothiazide was approved by FDA with ""CoDiovan"" as its brand name; New developed amlodipine/valsartan (Exforge) was also approved to the market.
There are many enterprises producing APIs and finished products of Valsartan. The market share of finished products is mainly occupied by Novartis, which is above 85% by sales value every year.
In China, the number of hypertensive patients has exceeded 200 million so the market prospect of Valsartan is bright.
Through this report, the readers can acquire the following information:
- Market Share of Major Valsartan Manufacturers in Sampling Hospitals in China
- Sales price of valsartan in hospital market in China
- Major valsartan enterprises in China
- Market share of valsartan by dosage form in hospital market in China
- Prospect of China valsartan market
The Following Enterprises and People Are Recommended to Purchase This Report:
-Valsartan API and finished product manufacturers
- Investors /research agencies focusing on valsartan market
1 Relevant Concepts of Valsartan
1.2 Sales Status on the Global Market
2 Market Overview of Valsartan in China
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size
3 Investigation on Sales Value of Valsartan in China, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region
4 Investigation on Market Share of Major Valsartan Manufacturers in China, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 Investigation on Market Size of Valsartan by Dosage Form in China, 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form
6 Reference Price of Valsartan in Hospital Market in China, 2013
6.1 Tianda Group
6.2 Livzon Pharmaceutical Factory of Livzon Group
6.3 Beijing Novartis Pharma Co., Ltd.
6.4 Beijing Saike Pharmaceutical Co., Ltd.
6.5 Guilin Winsun Pharmaceutical Co., Ltd.
6.6 Changzhou Siyao Pharmaceutical Co., Ltd.
6.7 Hainan Bright Future Pharmaceutical Co.,Ltd.
6.8 Hainan Hualon Pharmaceutical Co., Ltd.
7 Anallysis on Major Valsartan Manufacturers in China, 2009-2013
7.1 Beijing Novartis
7.2 Beijing Saike
7.3 Changzhou Siyao
7.4 Hainan Hualon
7.5 Lunan Better
8 Prospect of China Valsartan Market, 2014-2018
8.1 Forecast on Market Size
8.2 Forecast on Competition Pattern
Chart Valsartan Products Approved to Market in China, 2014
Chart Forecast on Market Size of Hospital-use Valsartan in China, 2014-2018
Chart Sales Value of Valsartan in Global Market, 2009-2013
Chart Sales Value of Valsartan in Hospital Market in China, 2009-2013
Chart Sales Value of Valsartan by Region in China, 2009-2013
Chart Market Share of Valsartan Enterprises by Sales Value in China, 2009-2013
Chart Hospital Price of Valsartan Produced by Tianda Group
Chart Hospital Price of Valsartan Produced by Beijing Novartis
- Tianda Group
- Livzon Pharmaceutical Factory of Livzon Group
- Beijing Novartis Pharma Co., Ltd.
- Beijing Saike Pharmaceutical Co., Ltd.
- Guilin Winsun Pharmaceutical Co., Ltd.
- Changzhou Siyao Pharmaceutical Co., Ltd.
- Hainan Bright Future Pharmaceutical Co.,Ltd.
- Hainan Hualon Pharmaceutical Co., Ltd.